| Literature DB >> 28531112 |
Rosanna Mattera1, Monica Benvenuto2, Maria Gabriella Giganti3, Ilaria Tresoldi4, Francesca Romana Pluchinotta5, Sonia Bergante6, Guido Tettamanti7, Laura Masuelli8, Vittorio Manzari9, Andrea Modesti10,11, Roberto Bei12,13.
Abstract
Cardiovascular diseases are the main cause of mortality and morbidity in the world. Hypertension, ischemia/reperfusion, diabetes and anti-cancer drugs contribute to heart failure through oxidative and nitrosative stresses which cause cardiomyocytes nuclear and mitochondrial DNA damage, denaturation of intracellular proteins, lipid peroxidation and inflammation. Oxidative or nitrosative stress-mediated injury lead to cardiomyocytes apoptosis or necrosis. The reactive oxygen (ROS) and nitrogen species (RNS) concentration is dependent on their production and on the expression and activity of anti-oxidant enzymes. Polyphenols are a large group of natural compounds ubiquitously expressed in plants, and epidemiological studies have shown associations between a diet rich in polyphenols and the prevention of various ROS-mediated human diseases. Polyphenols reduce cardiomyocytes damage, necrosis, apoptosis, infarct size and improve cardiac function by decreasing oxidative stress-induced production of ROS or RNS. These effects are achieved by the ability of polyphenols to modulate the expression and activity of anti-oxidant enzymes and several signaling pathways involved in cells survival. This report reviews current knowledge on the potential anti-oxidative effects of polyphenols to control the cardiotoxicity induced by ROS and RNS stress.Entities:
Keywords: cardiomyocytes; cardiovascular disease; oxidative stress; polyphenols
Mesh:
Substances:
Year: 2017 PMID: 28531112 PMCID: PMC5452253 DOI: 10.3390/nu9050523
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Generation of reactive oxygen species (ROS) and their cellular effects.
Figure 2Chemical structure of polyphenols.
In vitro protective effects of polyphenols against the oxidative stress-induced cardiotoxicity.
| Polyphenol | Cardiac Damage Inducers | Cell Type | In Vitro Effects | Ref. |
|---|---|---|---|---|
| Quercetin | DOX | H9c2 cells | ↓ Apoptosis, ROS, LDH release | [ |
| 3′- | H2O2 | H9c2 cells | ↓ Apoptosis and LDH release | [ |
| Hydroxytyrosol | Xanthine/XO | H9c2 cells | ↑ Phopsho-ERK1/2 and -Hsp-27 | [ |
| Taxifolin | Ang II | Neonatal rat cardiomyocytes | ↓ ROS and hypertrophy | [ |
| Rhamnetin | H2O2 | H9c2 cells | ↓ Apoptosis and ROS | [ |
| Isorhamnetin | DOX | H9c2 cells | ↓ Apoptosis and ROS | [ |
| Dihydromyricetin | DOX | Primary myocardial | ↓ Apoptosis and ROS | [ |
| Kaempferol | DOX | H9c2 cells | ↓ Apoptosis and ROS | [ |
| 3′,4′-dihydroxyflavonol | I/R | Cardiomyocytes | ↓ Superoxide | [ |
| Apigenin | A/R | H9c2 cells | ↓ Apoptosis and ROS | [ |
| Apigenin glucoside, vitexin | A/R | Neonatal rat cardiomyocytes | ↓ Apoptosis and ROS | [ |
| Baicalein | Ipoxia | Chick cardiomyocytes | ↓ Apoptosis and ROS | [ |
| EGCG | H2O2
| Neonatal and adult rat cardiomyocytes | ↓ Apoptosis and ROS | [ |
| EGCG and TF3 | H2O2 | Neonatal rat cardiomyocytes | ↓ Cellular damage | [ |
| (−)-epicatechin, avicularin and quercitrin | BSO | H9c2 cells | ↓ Apoptosis and LDH release | [ |
| Grape seed proanthocyanidin extract | I/R | Chick cardiomyocytes | ↓ Apoptosis and ROS | [ |
| Malvidin | I/R | Rat cardiomyocytes | ↑ LV pressure, Akt, eNOS, ERK1/2, and phospho-GSK3β | [ |
| Cyanidin-3- | I/R | Rat cardiomyocytes | ↓ Apoptosis and LDH release | [ |
| Blueberry phenol fractions | NE | Adult rat cardiomyocytes | ↓ Apoptosis and calpains | [ |
| Narigenin | H2O2 | H9c2 cells | ↓ Apoptosis and lipid peroxidation | [ |
| Naringin | High glucose | H9c2 cells | ↓ Apoptosis and ROS | [ |
| Naringenin-7- | DOX | H9c2 cells | ↓ Apoptosis and ROS | [ |
| Hesperetin | LPS | H9c2 cells | ↓ Apoptosis | [ |
| Puerarin | Ang II | Neonatal murine cardiomyocytes | ↓ ROS | [ |
| Calycosin | H2O2 | H9c2 cells | ↓ Apoptosis | [ |
| Licochalcone D | I/R | Rat cardiomyocytes | ↓ Caspase 3 and PARP | [ |
| Isoliquiritigenin | I/R | Cardiomyocytes | ↓ ROS and mitochondrial potential | [ |
| Safflor yellow A | A/R | Neonatal rat cardiomyocytes | ↓ LDH, CK, MDA and Bax | [ |
| Hydroxysafflor yellow A | A/R | H9c2 cells | ↓ Apoptosis | [ |
| Chalcone derivative L6H9 | Glucose | H9c2 cells | ↓ ROS, Hypertrophy and fibrosis | [ |
| Aspalathin | Hyperglycemia | H9c2 cells | ↓ ROS | [ |
| GLG | H2O2 | H9c2 cells | ↓ Apoptosis, ROS and hemolysis | [ |
| CSM-bark extract | H2O2 | Neonatal cardiomyocytes | ↓ Apoptosis and ROS | [ |
| Hispidin | H2O2 | H9c2 cells | ↓ Apoptosis, ROS and LDH release | [ |
| Methyl gallate | H2O2 | Neonatal rat cardiomyocytes | ↓ Apoptosis and ROS | [ |
| Pyrrolidinyl caffeamide | H2O2 | HL-1 cells | ↓ Apoptosis and ROS | [ |
| Ferulic acid | High glucose | Cardiomyocytes | ↓ Apoptosis and ROS | [ |
| MPE | Malathion | H9c2 cells | ↓ ROS, DPPH, ABTS and NO | [ |
| Hydroxycinnamic acids | DOX | Neonatal rat cardiomyocytes | ↓ Cellular damage and lipid peroxidation | [ |
| Danshensu | I/R | H9c2 cells | ↓ Apoptosis, ROS, LDH release, CK, MDA and caspase 3 | [ |
| Sch B | I/R | H9c2 cells | ↓ Apoptosis, inflammation and ROS | [ |
| Syringaresinol | I/R | H9c2 cells | ↓ ROS, MDA, Bax/Bcl-2 ratio, caspase 3 and HIF-1 | [ |
| Sesamin | DOX | H9c2 cells | ↓ Apoptosis, ROS and MDA | [ |
| Resveratrol | H2O2
| H9c2 cells | ↓ Apoptosis, necrosis, autophagy, mitochondrial dysfunction and cell injury | [ |
| Polydatin | Phenylephrine | Neonatal rat cardiomyocytes | ↓ ROS and RhoA/ROCK | [ |
| Bakuchiol | I/R | Rat cardiomyocytes | ↓ Apoptosis | [ |
| Curcumin | TNF-α | Rat cardiomyocytes | ↓ Apoptosis, ROS, NADPH oxidase, MDA, lipid peroxidation and protein carbonylation | [ |
| Nanocurcumin | Hypoxia | H9c2 cells | ↓ Apoptosis, hypertrophy and ROS | [ |
| Curcumin analogue 14p | I/R | H9c2 cells | ↓ Apoptosis, ROS and MDA | [ |
| Salvianolic acid B | TNF-α | HASMC | ↓ ROS, NADPH oxidase, MMP-2 | [ |
| Silymarin | Copper-ascorbate | Neonatal rat cardiomyocytes | ↓ ROS, NO, protein carbonylation and lipid peroxidation | [ |
| Silibinin | H2O2
| H9c2 cells | ↓ Apoptosis, DNA damage, ROS | [ |
| 2,3-dehydrosilybin | H/R | Neonatal rat cardiomyocytes | ↓ ROS, protein carbonylation and LDH release | [ |
| TFCC | DOX | H9c2 cells | ↓ Apoptosis, ROS, MDA and LDH release | [ |
Abbreviations: ↑: increase; ↓: decrease; DOX: doxorubicin; H2O2: hydrogen peroxide; A/R: anoxia/reoxygenation; XO: xanthine oxidase; ROS: reactive oxygen species; ERK: extracellular signal-regulated kinase; JNK: c-jun N-terminal kinase; TNF-α: tumor necrosis factor-α; PKCƐ: Protein kinase C epsilon type; ∆ψm: mitochondrial membrane potential; LDH: lactate dehydrogenase; MAPKAPK-2: mitogen-activated protein kinase-activated protein kinase 2; Hsp: heat shock protein; Ang II: angiotensin II; CAT: catalase; MnSOD: manganese superoxide dismutase; GSH: glutathione; SIRT1: sirtuin 1; mPTP: mitochondrial permeability transition pore; I/R: ischemia/reperfusion; CK: creatin kinase; H/R: hypoxia/reoxygenation; hESC-CMs: human embryonic stem cells-derived cardiomyocytes; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1; EGCG: (−)-epigallocatechin-3-gallate; MDA: malondialdehyde; GSH-Px: glutathione peroxidase; TF3: theaflavin-3,3′ digallate; BSO: buthionine-(S,R)-sulfoximine; NO: nitric oxide; GSSG: glutathione disulfide; LV: left ventricular; NE: norepinephrine; GCL: glutamate cysteine ligase; NQO-1: NAD(P)H:quinone oxidoreductase 1; LPS: lipopolysaccharide; ER: estrogen receptor; IL: interleukin; CRP: C reactive protein; eNOS: endothelial nitric oxide synthase; COX: cycloxygenase; GCLC: glutamate cysteine ligase catalytic subunit; GLG: Gui-ling-gao; CSM: Castanea Sativa Mill.; MPE: gallic acid-enriched methanolic Syzygium cumini pulp extract; DPPH: 1,1-diphenyl-1-picrylhydrazyl; ABTS: 2,2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid); Sch: schisandrin; HIF-1: hypoxia inducible factor-1; FoxO: Forkhead box protein O; T-AOC: total antioxidant capacity; AZT: azidothymidine; As2O3: arsenic trioxide; CaMKII: Ca2+/Calmodulin-dependent protein kinases II; GR: glutathione reductase; GST: glutathione s-transferase; TLR2: Toll-like receptor 2; MCP-1: monocyte chemoattractant protein; SDH: succinate dehydrogenase; HVCM: primary human ventricular cardiomyocytes; HASMC: human aortic smooth muscle cells; MMP: metalloproteinase; PDH: piruvate dehydrogenase; TFCC: Clinopodium chinense (Benth.) O. Ktze.
In vivo protective effects of polyphenols against the oxidative stress-induced cardiotoxicity.
| Polyphenol | In Vivo Model | Protective Effects | Ref. |
|---|---|---|---|
| Quercetin | Mice treated with DOX | ↑ Cardiac function | [ |
| Rats treated with DOX | ↓ Blood pressure and heart rate increase | [ | |
| Vincristine and quercetin | Rats exposed to isoproterenol | ↓ CK-MB, LDH, ALT, cTnT | [ |
| Taxifolin | Mouse model of TAC | ↓ Pressure overload, fibrosis, ROS, MDA, HNE | [ |
| DiOHF | Sheep model of I/R injury | ↓ ROS, neutrophil accumulation, LVDP, infarct size | [ |
| Isorhamnetin | Rats treated with DOX | ↓ Cardiac enzymes, apoptosis, ROS, lipid peroxidation | [ |
| Rutin | Rats exposed to sodium fluoride | ↓ Cardiac dysfunction, cardiac serum markers | [ |
| Dihydromyricetin | Mice treated with DOX | ↑ Survival rate | [ |
| Kaempferol | Rats treated with DOX | ↑ Body and heart weights, SOD, CAT | [ |
| Rat model of I/R injury | ↑ Cardiac function, SOD activity, GSH/GSSG ratio | [ | |
| Astragalin | Rat model of I/R injury | ↑ Cardiac function, SOD activity, GSH/GSSG ratio | [ |
| Baicalein | Murine model of I/R injury | ↓ Infarct size, apoptosis, pro-inflammatory cytokines | [ |
| Apigenin | Rat model of I/R injury | ↓ Infarct size, apoptosis, CK, LDH, MDA levels | [ |
| Vitexin | Rat model of I/R injury | ↑ Cardiac function, SOD activity | [ |
| Luteolin | Rat model of I/R injury | ↑ Cardiac function, MnSOD activity | [ |
| Breviscapine | Rat model of I/R injury | ↓ ICAM-1, ROS, MDA | [ |
| Green Tea Exctract (GTE) | Rat model of I/R injury | ↓ Infarct size, apoptosis | [ |
| Rats treated with DOX | ↓ AST, CK, LDH, lipid peroxidation | [ | |
| EGCG, quercetin | Rats with cardiac hypertrophy | ↓ Systolic blood pressure, heart weight indices, MDA | [ |
| GSP | Rats treated with cadmium | ↓ Cardiac damage, CK-MB, AST, ALT, ALP, LDH | [ |
| Procyanidins | Rats treated with DOX | ↑ Cardiac function | [ |
| BAE | Rats treated with CTX | ↑ Cardiac function , IL-10, SOD, GSH | [ |
| Hesperidin | Rat model of I/R injury | ↑ Cardiac function | [ |
| Naringin | Rat model of I/R injury | ↓ CK-MB, LDH, apoptosis, infarct size, inflammation | [ |
| Hesperetin | Rats treated with DOX | ↓ MDA, DNA damage | [ |
| Hesperidin | Rats treated with isoproterenol | ↓ Lipid peroxidation | [ |
| Hesperidin, naringin | HFD/STZ-induced diabetic rats | Prevention of diabetic complications | [ |
| Puerarin | Mice treated with Ang II | ↓ Cardiac hypertrophy, HW/BW, LVW/BW | [ |
| Rats subjected to severe burn | ↓ CK-MB, cTnT, MDA, MPO | [ | |
| Calycosin-7- | Rat model of I/R injury | ↑ Cardiac function, SOD activity | [ |
| Chalcone derivative L6H9 | STZ-induced diabetic mice | ↓ Cardiac damage and fibrosis | [ |
| Licochalcone B | Rat model of I/R injury | ↓ Apoptosis, MDA, LDH, CK, TNF-α | [ |
| Cl-chalcone, F-chalcone | Rat model of I/R injury | ↓ Infarct size, lipid peroxidation, MDA | [ |
| Pyrrolidinyl caffeamide (PLCA) | Rat model of I/R injury | ↓ Troponin, MDA, MPO | [ |
| Danshensu | I/R in spontaneously hypertensive rats (SHR) | ↓ Blood pressure increase, arrhythmias, HW/BW | [ |
| Rat model of I/R injury | ↓ Infarct size, CK-MB, cTnI | [ | |
| Shenge | Rats subjected to LAD | ↓ ST-segment elevation, infarct size | [ |
| Schisandrin B (Sch B) | Rats treated with DOX | ↓ CK, CK-MB, LDH, AST, MDA, MMP | [ |
| Mice treated with DOX | ↓ Cardiac damage, apoptosis, DNA damage | [ | |
| Mouse model of myocardial infarction (MI) | ↑ Survival rate, heart function, eNOS | [ | |
| Rat model of I/R injury | ↑ GSH | [ | |
| Magnolol | Rat model of I/R injury | ↓ Infarct size, apoptosis, myocardial dysfunction | [ |
| Sesamin | SHR rats | ↓ Cardiac fibrosis, systolic blood pressure | [ |
| Rats treated with DOX | Normalization QT intervals, QRS complexes | [ | |
| Deoxyshizandrin (DSD) + Schisantherin (STA) | Rat model of I/R injury | ↓ Infarct size, LVDP, arrhythmias, MDA | [ |
| Resveratrol | SHR rats | ↓ H2O2, left ventricular hypertrophy | [ |
| Mice treated with arsenic trioxide (As2O3) | ↓ QT-interval prolongation, cardiac damage, LDH | [ | |
| Mice treated with LPS | ↑ SERCA2a, Nrf2 | [ | |
| Rats treated with cisplatin | ↓ LDH, CK, MDA | [ | |
| Rats treated with DOX | ↓ Cardiac dysfunction, apoptosis, MDA, CK, LDH | [ | |
| STZ-induced diabetic mice | ↓ Apoptosis, p62 | [ | |
| Polydatin + vitamin C | Rats treated with DOX | ↓ ROS, MDA, CRP, ST and QT intervals | [ |
| Polydatin | Mice subjected to TAC | ↓ Cardiac hypertrophy | [ |
| Curcumin | Rat model of I/R | ↓ Lipid peroxidation | [ |
| Rats treated with isoprenaline | ↓ Apoptosis, MPO, MDA | [ | |
| Rat model of I/R | ↑ SIRT1, Bcl-2, SDH, COX | [ | |
| STZ-induced diabetic rats | ↓ MDA, hypertrophy, fibrosis, ventricular dysfunction | [ | |
| Curcumin + nebivolol | Rats treated with DOX | ↑ Survival rate, SOD, GSH-Px, Body and heart weights | [ |
| Oleuropein | Rats treated with DOX | ↓ CK, CK-MB, LDH, ALT, AST, apoptosis | [ |
| Silymarin | Rats treated with DOX | ↓ CK, LDH, creatinine, urea, MDA | [ |
| Rats treated with cisplatin | ↓ LDH, CK, CK-MB, cTnI, MDA | [ | |
| Mice treated with acrolein | ↓ Lipid peroxidation, apoptosis, MDA, cTnI, CK-MB | [ | |
| Silibinin | Rats treated with arsenic | ↑ Cardiac function, Nrf-2, HO-1 | [ |
| Rats treated with DOX | ↑ Body and heart weights | [ |
Abbreviations: ↑: increase, ↓: decrease; DOX: doxorubicin; ROS: reactive oxygen species; SOD: superoxide dismutase; MMP: metalloproteinase; CK-MB: creatin kinase-MB; LDH: lactate dehydrogenase; ALT: alanine aminotransferase; cTn: cardiac troponin; CAT: catalase; GR: glutathione reductase; GSH-Px: glutathione peroxidase; TAC: transverse aortic constriction; MDA: malondialdehyde; HNE: 4-hydroxy-2-nonenal; ANP: atrial natriuretic peptide; BNP: brain natriuretic peptide; ERK: extracellular signal-regulated kinase; JNK: c-jun N-terminal kinase; DiOHF: 3′,4′-dihydroxyflavonol; I/R: ischemia/reperfusion; LVDP: left ventricular end diastolic pressure; GSH: glutathione; AST: aspartate aminotransferase; GSSG: glutathione disulfide; MnSOD: manganese superoxide dismutase; EGCG: (−)-epigallocatechin-3-gallate; IL: interleukin; GCL: glutamate cysteine ligase; QR: quinone reductase; Cyt: cytochrome; GST: glutathione s-transferase; GSP: grape seed proanthocyanidins; ALP: alkaline phosphatase; G6PD: glucose-6-phosphate dehydrogenase; BAE: blueberry anthocyanins-enriched extracts: CTX: cyclophosphamide; HFD/STZ: high fat diet/streptozotocin; Ang II: angiotensin II; HW/BW: heart weight/body weight ratio; LVW/BW: left ventricular weight/body weight ratio; MPO: myeloperoxidase; TNF-α: tumor necrosis factor-α; COX: cyclooxygenase; HO-1: heme oxygenase-1; NQO-1: NAD(P)H:quinone oxidoreductase 1; GCLC: glutamate cysteine ligase catalytic subunit; NO: nitric oxide; iNOS: inducible nitric oxide sinthase; LAD: left anterior descending; SHR: spontaneously hypertensive rats; SIRT1: sirtuin 1; LVSP: left ventricular systolic pressure; SERCA: sarcoplasmic reticulum Ca2+ ATPase; Nrf2: nuclear factor erythroid 2-related factor 2; CRP: C reactive protein; SDH: succinate dehydrogenase.
Figure 3In vitro and in vivo effects of polyphenols in cardiovascular disease.